• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

立场文件:资源匮乏环境下错配修复缺陷综合征的挑战与具体策略。

Position paper: Challenges and specific strategies for constitutional mismatch repair deficiency syndrome in low-resource settings.

机构信息

Division of Pediatric Hematology-Oncology, Oncology Institute, Istanbul University, Istanbul, Turkey.

Department of Pediatrics, King Hussein Cancer Center, Hematology/Oncology, Amman, Jordan.

出版信息

Pediatr Blood Cancer. 2020 Aug;67(8):e28309. doi: 10.1002/pbc.28309. Epub 2020 May 30.

DOI:10.1002/pbc.28309
PMID:32472748
Abstract

Germline biallelic mutations in one of the mismatch repair genes, mutS homolog 2, mutS homolog 6, mutL homolog 1, or postmeiotic segregation increased 2, result in one of the most aggressive cancer syndromes in humans termed as constitutional mismatch repair deficiency (CMMRD). Individuals with CMMRD are affected with multiple tumors arising from multiple organs during childhood, and these individuals rarely reach adulthood without specific interventions. The most common tumors observed are central nervous system, hematological, and gastrointestinal malignancies. The incidence of CMMRD is expected to be high in low-resource settings due to a high rate of consanguinity in these regions, and it is thought to be underrecognized and consequently underdiagnosed. This position paper is therefore important to provide a summary of the current situation, and to highlight the necessity of increasing awareness, diagnostic criteria, and surveillance to improve survival for patients and family members.

摘要

种系双等位基因突变一个错配修复基因,如 mutS 同源物 2、mutS 同源物 6、mutL 同源物 1 或减数后分离增加 2,会导致人类最具侵袭性的癌症综合征之一,即组成性错配修复缺陷(CMMRD)。CMMRD 患者在儿童期就会受到来自多个器官的多种肿瘤的影响,如果没有特定的干预措施,这些患者很少能成年。最常见的观察到的肿瘤是中枢神经系统、血液和胃肠道恶性肿瘤。由于这些地区存在很高的近亲结婚率,预计资源匮乏地区的 CMMRD 发病率会很高,而且由于认识不足,因此可能会漏诊。因此,本立场文件的重要性在于提供当前情况的总结,并强调提高认识、诊断标准和监测的必要性,以改善患者和家庭成员的生存率。

相似文献

1
Position paper: Challenges and specific strategies for constitutional mismatch repair deficiency syndrome in low-resource settings.立场文件:资源匮乏环境下错配修复缺陷综合征的挑战与具体策略。
Pediatr Blood Cancer. 2020 Aug;67(8):e28309. doi: 10.1002/pbc.28309. Epub 2020 May 30.
2
Constitutional Mismatch Repair Deficiency in Israel: High Proportion of Founder Mutations in MMR Genes and Consanguinity.以色列的遗传性错配修复缺陷:错配修复基因中高比例的奠基者突变与近亲结婚
Pediatr Blood Cancer. 2016 Mar;63(3):418-27. doi: 10.1002/pbc.25818. Epub 2015 Nov 6.
3
[Constitutional MMR deficiency: Genetic bases and clinical implications].[先天性麻疹、腮腺炎、风疹疫苗(MMR)缺陷:遗传基础及临床意义]
Bull Cancer. 2019 Feb;106(2):162-172. doi: 10.1016/j.bulcan.2018.10.008. Epub 2018 Dec 11.
4
Connections between constitutional mismatch repair deficiency syndrome and neurofibromatosis type 1.先天性错配修复缺陷综合征与1型神经纤维瘤病之间的关联。
Clin Genet. 2017 Apr;91(4):507-519. doi: 10.1111/cge.12904. Epub 2017 Jan 10.
5
Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium.遗传和临床决定因素导致的错配修复缺陷综合征:来自错配修复缺陷综合征联盟的报告。
Eur J Cancer. 2014 Mar;50(5):987-96. doi: 10.1016/j.ejca.2013.12.005. Epub 2014 Jan 15.
6
Constitutional mismatch repair deficiency in a healthy child: On the spot diagnosis?健康儿童中存在的错配修复缺陷:现场诊断?
Clin Genet. 2018 Jan;93(1):134-137. doi: 10.1111/cge.13053. Epub 2017 Sep 15.
7
Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents.基于微卫星不稳定性和淋巴细胞对甲基化试剂的耐受诊断错配修复缺陷综合征。
Gastroenterology. 2015 Oct;149(4):1017-29.e3. doi: 10.1053/j.gastro.2015.06.013. Epub 2015 Jun 25.
8
Cancer and constitutional Mismatch Repair Deficiency syndrome due to homozygous MSH 6 mutation in children with Café au Lait Spots and review of literature.患有咖啡斑的儿童中因纯合子MSH 6突变导致的癌症和遗传性错配修复缺陷综合征及文献综述
Turk J Pediatr. 2021;63(5):893-902. doi: 10.24953/turkjped.2021.05.017.
9
Constitutional Mismatch Repair Deficiency Syndromes, a Neurofibromatosis 1 Mimicker That Hinders Timely Management.错配修复缺陷综合征,一种类似神经纤维瘤病 1 型的疾病,会阻碍及时治疗。
J Pediatr Hematol Oncol. 2023 Jul 1;45(5):e613-e620. doi: 10.1097/MPH.0000000000002641. Epub 2023 Feb 20.
10
Cancer prevention by aspirin in children with Constitutional Mismatch Repair Deficiency (CMMRD).儿童错配修复缺陷(CMMRD)用阿司匹林预防癌症。
Eur J Hum Genet. 2018 Oct;26(10):1417-1423. doi: 10.1038/s41431-018-0197-0. Epub 2018 Jun 14.

引用本文的文献

1
An update on central nervous system tumors in germline replication-repair deficiency syndromes.种系复制修复缺陷综合征中枢神经系统肿瘤的最新进展
Neurooncol Adv. 2024 Jun 19;6(1):vdae102. doi: 10.1093/noajnl/vdae102. eCollection 2024 Jan-Dec.
2
Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti-PD-1 Monotherapy: A Report from the International RRD Consortium.联合免疫疗法改善抗 PD-1 单药治疗失败的复制修复缺陷(RRD)高级别胶质瘤的预后:来自国际 RRD 联盟的报告。
Cancer Discov. 2024 Feb 8;14(2):258-273. doi: 10.1158/2159-8290.CD-23-0559.
3
Using comprehensive genomic and functional analyses for resolving genotype-phenotype mismatches in children with suspected CMMRD in Lebanon: an IRRDC study.
利用全面的基因组和功能分析解决黎巴嫩疑似CMMRD儿童的基因型-表型不匹配问题:一项IRRDC研究。
Hum Genet. 2023 Apr;142(4):563-576. doi: 10.1007/s00439-023-02530-8. Epub 2023 Feb 15.
4
Immune Checkpoint Inhibition as Single Therapy for Synchronous Cancers Exhibiting Hypermutation: An IRRDC Study.免疫检查点抑制作为具有高突变的同步性癌症的单一疗法:一项IRRDC研究。
JCO Precis Oncol. 2022 Mar;6:e2100286. doi: 10.1200/PO.21.00286.
5
Do non-pathogenic variants of DNA mismatch repair genes modify neurofibroma load in neurofibromatosis type 1?DNA 错配修复基因的非致病性变异是否会改变 1 型神经纤维瘤病中的神经纤维瘤负担?
Childs Nerv Syst. 2022 Apr;38(4):705-713. doi: 10.1007/s00381-021-05436-w. Epub 2022 Jan 8.
6
Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance.行错配修复缺陷个体行监测的生存获益。
J Clin Oncol. 2021 Sep 1;39(25):2779-2790. doi: 10.1200/JCO.20.02636. Epub 2021 May 4.